Moderna is increasing its baseline production estimates for its coronavirus disease 2019 (COVID-19) vaccine, mRNA-1237, from 500 to 600 million doses for 2021, according to a statement issued by the Company.

It is expected that approximately 100 million doses of the vaccine will be available in the US by the end of the first quarter of 2021, with an additional 100 million doses available by the end of the second quarter.

According to the Company, 18 million doses have thus far been supplied to the US government; the US government has agreed to purchase 200 million doses of the vaccine with an option to buy an additional 300 million doses.

Continue Reading

Under the Food and Drug Administration’s Emergency Use Authorization, the Moderna COVID-19 vaccine has been authorized for active immunization to prevent COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 18 years of age and older. The mRNA-1273 (100μg) vaccine is administered intramuscularly as a series of 2 doses (0.5mL each), given 28 days apart. Patients who receive the Moderna COVID-19 vaccine should receive a second dose of the same vaccine to complete the series; there are currently no data available on the interchangeability of COVID-19 vaccines.

The product is supplied as a preservative-free frozen suspension in multi-dose vials. Unopened vials of mRNA-1273 vaccine remain stable at 2° to 8°C (36° to 46°F) for up to 30 days, -20° C (-4°F) for up to 6 months, and at room temperature for up to 12 hours.

For more information visit


Moderna Provides COVID-19 Vaccine Supply Update. [press release]. Cambridge, MA; Moderna, Inc.; January 4, 2021.

This article originally appeared on MPR